Bevacizumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26599 publications

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Journal: JAMA network open

Published: April 15, 2026

Visual Acuity and Durability Outcomes of Faricimab Compared With Other Anti-vascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Diabetic Macular Edema.

Visual Acuity and Durability Outcomes of Faricimab Compared With Other Anti-vascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Diabetic Macular Edema.

Journal: Journal of vitreoretinal diseases

Published: April 13, 2026

Visual Acuity and Durability Outcomes of Faricimab Compared With Other Antivascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Neovascular Age-Related Macular Degeneration.

Visual Acuity and Durability Outcomes of Faricimab Compared With Other Antivascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Neovascular Age-Related Macular Degeneration.

Journal: Journal of vitreoretinal diseases

Published: April 13, 2026

[89Zr]bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic NF2-related schwannomatosis: a study protocol for a phase II single centre, prospective, feasibility trial.

[89Zr]bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic NF2-related schwannomatosis: a study protocol for a phase II single centre, prospective, feasibility trial.

Journal: BMJ open

Published: April 08, 2026

Literature-based meta-analysis of adverse events accounting for heterogeneous follow-up duration in oncology clinical trials.

Literature-based meta-analysis of adverse events accounting for heterogeneous follow-up duration in oncology clinical trials.

Journal: Research synthesis methods

Published: April 08, 2026

Cost Analysis of Anti-VEGF With Laser Photocoagulation in the Treatment of Retinopathy of Prematurity at an Academic Referral Center.

Cost Analysis of Anti-VEGF With Laser Photocoagulation in the Treatment of Retinopathy of Prematurity at an Academic Referral Center.

Journal: Journal of vitreoretinal diseases

Published: April 07, 2026

Radiation Necrosis in Pediatric Proton Therapy for Central Nervous System Tumors: Current Evidence and Future Directions.

Radiation Necrosis in Pediatric Proton Therapy for Central Nervous System Tumors: Current Evidence and Future Directions.

Journal: Journal of child neurology

Published: April 07, 2026

Injected Eye, Fellow Eye and Systemic Pharmacokinetic Modeling of Intravitreally Administered Bevacizumab.

Injected Eye, Fellow Eye and Systemic Pharmacokinetic Modeling of Intravitreally Administered Bevacizumab.

Journal: Molecular pharmaceutics

Published: April 02, 2026

A Bispecific Antibody Engineering Strategy for Effective Dual-Target Degradation of Cell-Surface and Secreted Oncoproteins with Superior Antitumor Activity.

A Bispecific Antibody Engineering Strategy for Effective Dual-Target Degradation of Cell-Surface and Secreted Oncoproteins with Superior Antitumor Activity.

Journal: ACS chemical biology

Published: April 01, 2026

Choroidal Neovascularization as a Postpartum Complication of Gestational Hypertension: A Case Report.

Choroidal Neovascularization as a Postpartum Complication of Gestational Hypertension: A Case Report.

Journal: Retinal cases & brief reports

Published: April 01, 2026

Visualization of Multi-indication Randomized Control Trial Evidence to Support Decision Making in Oncology: A Case Study on Bevacizumab.

Visualization of Multi-indication Randomized Control Trial Evidence to Support Decision Making in Oncology: A Case Study on Bevacizumab.

Journal: Medical decision making : an international journal of the Society for Medical Decision Making

Published: March 31, 2026

Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study.

Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study.

Journal: ESMO gastrointestinal oncology

Published: March 27, 2026

Showing 1-12 of 26,599

Last Updated: 04/28/2026